Literature DB >> 21633043

Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus.

Justin R Darwin1, Joan L Kenney, Scott C Weaver.   

Abstract

Chikungunya virus (CHIKV) is an emerging, mosquito-borne alphavirus that has caused major epidemics in Africa and Asia. We developed chimeric vaccine candidates using the non-structural protein genes of either Venezuelan equine encephalitis virus (VEEV) attenuated vaccine strain TC-83 or a naturally attenuated strain of eastern equine encephalitis virus (EEEV) and the structural genes of CHIKV. Because the transmission of genetically modified live vaccine strains is undesirable because of the potentially unpredictable evolution of these viruses as well as the potential for reversion, we evaluated the ability of these vaccines to infect the urban CHIKV vectors, Aedes aegypti and Ae. albopictus. Both vaccine candidates exhibited significantly lower infection and dissemination rates compared with the parent alphaviruses. Intrathoracic inoculations indicated that reduced infectivity was mediated by midgut infection barriers in both species. These results indicate a low potential for transmission of these vaccine strains in the event that a vaccinee became viremic.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21633043      PMCID: PMC3110354          DOI: 10.4269/ajtmh.2011.11-0049

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features.

Authors:  M C ROBINSON
Journal:  Trans R Soc Trop Med Hyg       Date:  1955-01       Impact factor: 2.184

2.  An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology.

Authors:  W H LUMSDEN
Journal:  Trans R Soc Trop Med Hyg       Date:  1955-01       Impact factor: 2.184

3.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Authors:  R Edelman; C O Tacket; S S Wasserman; S A Bodison; J G Perry; J A Mangiafico
Journal:  Am J Trop Med Hyg       Date:  2000-06       Impact factor: 2.345

4.  Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area.

Authors:  S B Halstead; J E Scanlon; P Umpaivit; S Udomsakdi
Journal:  Am J Trop Med Hyg       Date:  1969-11       Impact factor: 2.345

5.  The 1964 chikungunya epidemic at Vellore, South India, including observations on concurrent dengue.

Authors:  D E Carey; R M Myers; C M DeRanitz; M Jadhav; R Reuben
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

6.  Chikungunya virus infection with haemorrhagic manifestations.

Authors:  J K Sarkar; S N Chatterjee; S K Chakravarti; A C Mitra
Journal:  Indian J Med Res       Date:  1965-10       Impact factor: 2.375

7.  Development of an attenuated strain of chikungunya virus for use in vaccine production.

Authors:  N H Levitt; H H Ramsburg; S E Hasty; P M Repik; F E Cole; H W Lupton
Journal:  Vaccine       Date:  1986-09       Impact factor: 3.641

8.  Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.

Authors:  T R Bhatt; M B Crabtree; F Guirakhoo; T P Monath; B R Miller
Journal:  Am J Trop Med Hyg       Date:  2000-04       Impact factor: 2.345

9.  Arthritides caused by mosquito-borne viruses.

Authors:  R B Tesh
Journal:  Annu Rev Med       Date:  1982       Impact factor: 13.739

10.  Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine.

Authors:  M J Turell; F J Malinoski
Journal:  Am J Trop Med Hyg       Date:  1992-07       Impact factor: 2.345

View more
  6 in total

Review 1.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

2.  Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.

Authors:  James Weger-Lucarelli; Matthew T Aliota; Nathan Wlodarchak; Attapon Kamlangdee; Ryan Swanson; Jorge E Osorio
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

3.  A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.

Authors:  Christopher Weber; Sarah M Büchner; Barbara S Schnierle
Journal:  PLoS Negl Trop Dis       Date:  2015-04-23

4.  Chikungunya Virus Vaccines: Viral Vector-Based Approaches.

Authors:  Katrin Ramsauer; Frédéric Tangy
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 5.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

Review 6.  Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy.

Authors:  Simon-Djamel Thiberville; Nanikaly Moyen; Laurence Dupuis-Maguiraga; Antoine Nougairede; Ernest A Gould; Pierre Roques; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2013-06-28       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.